Dataset from A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients With Severe Nasal Polyposis

The aim of this present study is to investigate the use of benralizumab as treatment for
severe nasal polyposis. The effect of benralizumab on nasal polyps will be assessed over a 56
weeks of treatment period in patients with severe bilateral nasal polyposis who are still
symptomatic despite standard of care therapy, i.e current use of intranasal corticosteroids
(INCS) and prior surgery and/or use of systemic corticosteroids. The first 200 patients that
complete the 56-week treatment will have a 6 month follow-up (FU) period without dosing.